Coherus BioSciences, Inc.

NasdaqGM CHRS

Coherus BioSciences, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 0.55

Coherus BioSciences, Inc. Price to Sales Ratio (P/S) is 0.55 on January 14, 2025, a -46.48% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Coherus BioSciences, Inc. 52-week high Price to Sales Ratio (P/S) is 1.24 on February 15, 2024, which is 126.60% above the current Price to Sales Ratio (P/S).
Coherus BioSciences, Inc. 52-week low Price to Sales Ratio (P/S) is 0.25 on November 04, 2024, which is -53.47% below the current Price to Sales Ratio (P/S).
Coherus BioSciences, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 0.66.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: CHRS

Coherus BioSciences, Inc.

CEO	Mr. Dennis M. Lanfear
IPO Date	Nov. 6, 2014
Location	United States
Headquarters	333 Twin Dolphin Drive
Employees	235
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Key trends

Past 5 years